TheNovo semaglutideNordisk's trialAlzheimer's drug failure actuallyis reinforcesa devastating blow that wiped $20 billion from the drugcompany's potentialmarket forvalue preventingin Alzheimer'sa beforesingle symptoms appearday. Real-worldThe dataDanish consistentlydrugmaker showdesperately peopleneeded onthis GLP-1win drugsafter havea loweryear dementiaof risksliding overshares manyand yearsslowing sales, whilebut theseits trialsown onlyexecutives lastedcalled twoit yearsa on"lottery patientsticket" withthat establishedturned diseaseout to be worthless. TheThis biomarkermassive improvements10% suggeststock thatplunge thisshows classinvestors ofhave drugslost couldconfidence reshapein theNovo's courseability ofto neurodegenerationescape whenthe usedquicksand earlierit's stuck in.

It'sThe asemaglutide verytrial badfailure dayactually forreinforces Alzheimerthe drug's treatmentpotential research.for Hopespreventing had been high for J&JAlzheimer's tau-targetingbefore antibody,symptoms seenappear. byReal-world manydata asconsistently ashow potentialpeople breakthroughon afterGLP-1 yearsdrugs ofhave setbackslower indementia therisk field.over Itsmany disappointingyears, outcomewhile underscoresthese howtrials difficultonly itlasted remainstwo toyears slowon orpatients haltwith thisestablished complex disease. ForThe patients,biomarker familiesimprovements andsuggest clinicians,that thethis newsclass is another painful reminder of the urgent need for drugs thatcould trulyreshape change the course of Alzheimer'sneurodegeneration when used earlier.

ThereIt's a 48%very chancebad thatday afor partialAlzheimer's reprogramming-basedtreatment therapyresearch. willHopes receivehad regulatorybeen approvalhigh for treating AlzheimerJ&J's diseasetau-targeting beforeantibody, Janseen by many as a potential breakthrough after years of setbacks in the field. 1Its disappointing outcome underscores how difficult it remains to slow or halt this complex disease. For patients, 2035families and clinicians, accordingthe tonews is another painful reminder of the Metaculusurgent predictionneed communityfor drugs that truly change the course of Alzheimer's.